SCHEMBL4623181

SCHEMBL4623181

NC1=Cc2ccccc2CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.50
CYP11B1 P15538 2/20 0.42
CYP11B2 P19099 2/20 0.42
CYP19A1 P11511 1/20 0.42
NISCH Q9Y2I1 1/20 0.41
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
GPR84 Q9NQS5 1/20 0.39
MAOB P27338 2/20 0.38
PTGS2 P35354 1/20 0.38
HTR1A P08908 1/20 0.38
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR7 P34969 1/20 0.38
HRH1 P35367 1/20 0.38
DRD3 P35462 1/20 0.38
HTR2B P41595 1/20 0.38
ADRA2A P08913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL626635 0.80 MAOA (0.44) KDM1ACYP11B1CYP11B2GPR84MAOB
Hydrochloric Acid SCHEMBL4604472 0.78 MAOA (0.42) KDM1ACYP11B1CYP11B2GPR84MAOB
Hydrochloric Acid SCHEMBL30361381 0.78 MAOA (0.42) KDM1ACYP11B1CYP11B2GPR84MAOB
Hydrochloric Acid SCHEMBL4604224 0.78 MAOA (0.42) KDM1ACYP11B1CYP11B2GPR84MAOB
SCHEMBL30762289 0.74 MEN1 (0.36) KDM1ANOS3NOS1NOS2KDM4E
SCHEMBL15961771 0.73 MAPT (0.40) KDM4EALDH1A1TSHR
SCHEMBL24386545 0.71 KDM1A (0.46) KDM1ACYP11B1CYP11B2CYP19A1NISCH
SCHEMBL5029738 0.71 KDM1A (0.46) KDM1ACYP11B1CYP11B2CYP19A1NISCH
SCHEMBL227232 0.71 KDM1A (0.46) KDM1ACYP11B1CYP11B2CYP19A1NISCH
SCHEMBL10419760 0.71 KDM1A (0.46) KDM1ACYP11B1CYP11B2CYP19A1NISCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585428-B1 PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S)-5-ALKOXY-2-AMINOTETRALIN DERIVATIVES UCB BIOPHARMA SPRL (BE) 2017-05-10 EP claimed
EP-1017377-B1 USE OF 6, 7-SUBSTITUTED 2-AMINOTETRALINES FOR THE TREATMENT OF CYTOKINE MEDIATED INFLAMMATORY CONDITIONS SIGMA TAU IND BR FARMACEUTICHE (IT) 2001-12-05 EP claimed
EP-0270947-B1 SUBSTITUTED BASIC 2-AMINOTETRALINES BAYER AG (DE) 1993-05-19 EP claimed
EP-0272534-A2 8-substituted 2-aminotetralins BAYER AG (DE) 1988-06-29 EP claimed
EP-0270947-A2 Substituted basic 2-aminotetralines BAYER AG (DE) 1988-06-15 EP claimed
EP-4395520-A2 LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE SAME Samsung Display Co., Ltd. (KR) 2024-07-03 EP disclosed
CN-106572658-B Molecule and relative intermediate, composition and method with certain disinsection efficiencies 美国陶氏益农公司 2019-11-08 CN disclosed
EP-1696905-B1 SUBSTITUTED 2-AMINOTETRALINES FOR THE PREVENTIVE TREATMENT OF PARKINSON'S DISEASE SANOL ARZNEI SCHWARZ GMBH (DE) 2008-03-19 EP disclosed
EP-1696905-B1 SUBSTITUTED 2-AMINOTETRALINES FOR THE PREVENTIVE TREATMENT OF PARKINSON'S DISEASE SANOL ARZNEI SCHWARZ GMBH (DE) 2008-03-19 EP disclosed
EP-1696905-A1 USE OF SUBSTITUTED 2-AMINOTETRALINES FOR THE PREVENTATIVE TREATMENT OF PARKINSON'S DISEASE SCHWARZ PHARMA AG (DE) 2006-09-06 EP disclosed
EP-1696905-A1 USE OF SUBSTITUTED 2-AMINOTETRALINES FOR THE PREVENTATIVE TREATMENT OF PARKINSON'S DISEASE SCHWARZ PHARMA AG (DE) 2006-09-06 EP disclosed
WO-2005063238-A1 USE OF SUBSTITUTED 2-AMINOTETRALINES FOR THE PREVENTATIVE TREATMENT OF PARKINSON'S DISEASE SCHWARZ PHARMA AG (DE) 2005-07-14 WO disclosed
WO-2005063238-A1 USE OF SUBSTITUTED 2-AMINOTETRALINES FOR THE PREVENTATIVE TREATMENT OF PARKINSON'S DISEASE SCHWARZ PHARMA AG (DE) 2005-07-14 WO disclosed
EP-0270947-B1 SUBSTITUTED BASIC 2-AMINOTETRALINES BAYER AG (DE) 1993-05-19 EP disclosed
EP-0270947-A2 Substituted basic 2-aminotetralines BAYER AG (DE) 1988-06-15 EP disclosed